Pharmaceutical Biotech (02269.HK): Opening a New Chapter in Global Operations, Multiple Engines Drive Growth
Pharmaceutical Biotech (2269.HK): The non-COVID-19 business continues to grow rapidly while the industry gradually recovers
Pharmaceutical Biotech (2269.HK) 2023 Report Review: Steady growth in revenue and profit is optimistic that the company's multiple technology platforms will drive the long-term growth of integrated CRDMO leaders
Pharmaceutical Biotech (02269.HK): The non-COVID-19 business maintained a high growth rate and the trend of new orders in 24 years was good
Pharmaceutical Biotech (02269.HK): Steady growth in the non-COVID-19 business, global production capacity layout continues to advance
WUXI BIOLOGICS(02269.HK):REBOUND OF THE NUMBER OF NEW PROJECTS
Pharmaceutical Biotech (2269.HK): Performance is in line with expectations, overseas production capacity is gradually being implemented
Pharmaceutical Biotech (02269.HK) 2023 Report Review: Regular Business Steady Growth, Production Capacity Construction Continues to Advance
Pharmaceutical Biotech (02269.HK): Steady revenue growth in 2023, business fundamentals are resilient
Pharmaceutical Biotech (2269.HK): Commercial production continues to expand, and the number of comprehensive projects is steadily increasing
WUXI BIOLOGICS(2269.HK):EXPAND OVERSEAS CAPACITY TO MITIGATE RISKS
Pharmaceutical Biotech (2269.HK) 2023 Annual Report Review: New global production capacity has been put into operation one after another to achieve steady growth in non-COVID-19 performance
Pharmaceutical Biotech (2269.HK): Performance is in line with expectations, and the number of new projects continues to be repaired
Damo: Maintain the target price of “gain” rating of Pharmacovigenics (02269) at HK$63.1
Pharmaceutical Biotech (02269.HK) Annual Report Review Report: Steady performance is in line with expectations, and the number of new projects can be expected to resume and continue to grow quarter by quarter
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy
Pharmaceutical Biotech (2269.HK): Draft US Bill Affects the Company's Continued Steady Development
Pharmaceutical Biotech (02269.HK): Empowering global partners to wait for the industry to bottom up
Pharmaceutical Biotech (2269.HK): 132 new comprehensive projects were added in 23, and there was a sharp rebound in the number of new projects in Q4
Pharmaceutical Biotech (02269.HK) Company Comment: Raising the target number of new projects in 2024 can be expected to grow rapidly
No Data